As scientists work on finding effective treatments against COVID-19, one new study confirms previous research that shows the drug hydroxychloroquine isn’t the answer.

当科学家们努力寻找对COVID-19的有效治疗方法时,一项新研究证实了先前的发现——羟氯喹药物并不是解决之道。



The researchers found that in patients with mild to moderate COVID-19, hydroxychloroquine used with or without azithromycin “did not improve clinical status at 15 days as compared with standard care.”

研究人员发现,在轻度至中度COVID-19的患者中,羟氯喹与阿奇霉素一起使用或单独使用羟氯喹“与标准护理相比,在15天时临床状况并未改善”。

What’s more, elevated liver enzymes and heart rhythm problems were “more frequent” in patients who received either hydroxychloroquine with azithromycin or hydroxychloroquine alone, according to the study.

更重要的是,根据这项研究,在接受羟氯喹联合阿奇霉素或仅接受羟氯喹治疗的患者中,肝酶升高和心律问题“更加频繁”。

The latest study results don’t come as a surprise to experts in light of previous research that had already dashed hopes for hydroxychloroquine as a coronavirus treatment, along with the Food and Drug Administration’s cautionary warning about using the drug outside of hospital or clinical trial settings because of “reports of serious heart rhythm problems and other safety issues, including blood and lymph system disorders, kidney injuries and liver problems and failure.”

鉴于之前的研究已经让羟氯喹作为冠状病毒治疗的希望破灭,以及食品和药物管理局对在医院或临床试验环境之外使用该药物的警告,最新的研究结果并没有让专家们感到惊讶,因为 "有报道称(使用了羟氯喹的患者)存在严重的心律问题和其他安全问题,包括血液和淋巴系统疾病、肾脏损伤和肝脏衰竭问题"。

“While there was initial potential reported for hydroxychloroquine and azithromycin, which largely consisted of small case studies, the validity and reliability of these findings were always in question,” Dr. Iahn Gonsenhauser, chief quality and patient safety officer at the Ohio State University Wexner Medical Center, tells Yahoo Life. “Not many of my colleagues in the scientific community are very surprised by the most recent NEJM study.”

"虽然最初有关于羟氯喹和阿奇霉素的潜在报道,主要是由小型病例研究组成,但这些研究结果的有效性和可靠性一直受到质疑,"俄亥俄州立大学韦克斯纳医学中心的首席质量和患者安全官员Iahn Gonsenhauser博士告诉雅虎生活。"我在科学界的同事中,没有多少人对NEJM的最新研究结果感到非常惊讶。"

Dr. Steven Nissen, chief academic officer for the Cleveland Clinic Heart, Vascular and Thoracic Institute, calls the pursuit of hydroxychloroquine as a treatment strategy “sheer madness” and tells Yahoo Life that “there has never been any good solid scientific evidence that it does work.”

克利夫兰诊所的心脏、血管和胸腔研究所首席学术官Steven Nissen博士称:追求羟氯喹作为治疗策略是 "纯粹的疯狂",并告诉雅虎生活,"从来没有任何好的、坚实的科学证据表明它确实有效"。

In addition, Dr. Dean Winslow, an infectious disease physician at Stanford Health Care, tells Yahoo Life that he was “very concerned” about the drug combination used in the study, which can cause heart rhythm changes.

此外,斯坦福医疗中心的传染病医生Dean Winslow博士告诉雅虎生活,他对研究中使用的药物组合 "非常担心",因为它可能会导致患者心律变化。

“Both macrolide antibiotics [like azithromycin] and antimalarial drugs [like hydroxychloroquine] have the potential of prolonging the QT interval [the time between the heart muscle contracting and relaxing] in EKGs and can cause fatal arrhythmias and increased mortality,” he explains.

“大环内酯类抗生素(如阿奇霉素)和抗疟疾药物(如羟氯喹)都有可能延长心电图的QT间隔(心肌收缩和放松的时间),并可能导致致命性心律不齐和死亡率增加,”他解释说。

Adds Winslow: “This is further evidence that this is not a winning strategy. I think we’ve studied it enough.”

Winslow补充道:"这进一步证明了这不是一个成功的策略。我认为我们研究已经足够了。"

Nissen agrees, saying: “It’s time to stop pursuing this. It’s time to move on and study something that has a chance to help people.”

Nissen表示同意,他说。"是时候停止尝试这个药物了。现在应该继续前进,研究一些可以帮助人们的东西。"

He also expressed his frustration with how treatments that haven’t been fully vetted are being prematurely announced. “Desperation is not a scientific strategy,” Nissen says. “We have people throwing spaghetti at the wall and seeing what sticks. We need a nationally coordinated strategy [of scientists] who understand clinical trials, and we just don’t have it.”

对于过早宣布尚未完全审查的治疗方法,他也表示失望。"铤而走险不是一个科学的策略,"Nissen说。"我们有人向墙上扔意大利面条,看看有没有粘住东西(歇后语,原意是验证意大利面是否煮熟,结合本文意为鲁莽地尝试各种治疗药物是否有效)。我们需要[科学家]全国协调战略,他们了解临床试验,但我们还没有(这样做)。"

In the meantime, there are several treatments that have been beneficial to patients with the coronavirus, according to Gonsenhauser: “Convalescent plasma, a specific component of blood donated by COVID survivors that includes the immune cells their body generated to fight the virus; dexamethasone [a medical steroid], which has been used to combat extreme inflammation for a long time and has been shown to improve outcomes; and remdesivir, a drug that limits virus replication and has been shown to decrease the time it takes to recover from COVID, but may or may not improve the risk of dying.”

与此同时,根据Gonsenhauser的说法,有几种治疗方法对冠状病毒患者有益:"康复血浆,这是COVID-19康复者捐献的血液中的一种特殊成分,其中包括他们身体产生的免疫细胞,可用来对抗病毒;地塞米松[一种医用类固醇],长期以来一直被用于对抗极端的炎症,并已被证明可以改善治疗结果;雷米西韦,一种限制病毒复制的药物,已被证明可以减少从COVID-19中恢复所需的时间,但可能会也可能不会增加死亡风险。"

Another promising drug currently being studied is the oral medication favipiravir. “So far it seems to be very safe and well tolerated overall,” says Winslow.

目前正在研究的另一种有前途的药物是口服药物-法维拉韦 。"到目前为止,它似乎是非常安全的,总体上耐受性很好," Winslow说。

He notes that even though we’re “making progress slowly” in terms of treatment strategies, Winslow explains that’s because the coronavirus is a challenging and “very virulent pathogen.”

他指出,尽管我们在治疗策略方面 "进展缓慢",但Winslow解释说,这是因为冠状病毒是一种具有挑战性和 "非常致命的病原体"。

“COVID is commanding an incredible amount of attention and work,” Gonsenhauser says. “Vaccine studies appear to be moving incredibly quickly, and we seem to learn more about the virus every day, ... It would be surprising if additional treatments are not identified, but at the same time, viruses are very tricky [and] the science is complicated, so it also wouldn’t be terribly surprising if the discoveries are limited.”

"COVID引起了非常多的关注和工作,"Gonsenhauser说。"疫苗研究似乎进展得非常快,我们似乎每天都在了解更多关于病毒的信息,...。如果没有发现更多的治疗方法,那将是令人惊讶的,但同时,病毒是非常棘手的[并且]科学是复杂的,所以如果发现是有限的,也不会非常令人惊讶。"

He adds: “In the meantime, masks for everyone, social distance and hand hygiene are the best efforts to all focus on.”

他补充道:"同时,每个人佩戴口罩,保持社交距离和手部卫生是所有努力里最有效的。"

The study’s authors didn’t immediately respond to Yahoo Life’s request for comment.

该研究的作者没有立即回应雅虎生活的评论请求。